Toggle Main Menu Toggle Search

Open Access padlockePrints

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

Lookup NU author(s): Jess Tyerman, Dr Christopher DuncanORCiD, Dr Rebecca PayneORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Pronounced immune escape by the SARS-CoV-2 Omicron variant has resulted inmany individuals possessing hybrid immunity, generated through a combination ofvaccination and infection. Concerns have been raised that omicron breakthroughinfections in triple-vaccinated individuals result in poor induction of omicron-specific immunity, and that prior SARS-CoV-2 infection is associated with immune dampening.Taking a broad and comprehensive approach, we characterize mucosal and bloodimmunity to spike and non-spike antigens following BA.1/BA.2 infections in triplemRNA-vaccinated individuals, with and without prior SARS-CoV-2 infection. We findthat most individuals increase BA.1/BA.2/BA.5-specific neutralising antibodiesfollowing infection, but confirm that the magnitude of increase and post-omicron titresare higher in the infection-naive. In contrast, significant increases in nasal responses, including neutralizing activity against BA.5 spike, are seen regardless of infection history. Spike-specific T cells increase only in infection-naive vaccinees; however,post-omicron T cell responses are significantly higher in the previously-infected, whodisplay a maximally induced response with a highly cytotoxic CD8+ phenotypefollowing their 3rd mRNA vaccine dose. Responses to non-spike antigens increasesignificantly regardless of prior infection status. These findings suggest that hybridimmunity induced by omicron breakthrough infections is characterized by significantimmune enhancement that can help protect against future omicron variants.


Publication metadata

Author(s): Hornsby H, Nicols A, Longet S, Liu C, Tomic A, Angyal A, Kronsteiner B, Tyerman J, Tipton T, Zhang P, Gallis M, Supasa P, Selvaraj M, Abraham P, Neale I, Ali M, Barratt N, Nell J, Gustafsson L, Strickland S, Grouneva I, Rostron T, Moore S, Hering L, Dobson S, Bibi S, Mongkolsapaya J, Lambe T, Wootton D, Hall V, Hopkins S, Dong T, Barnes E, Screaton G, Richter A, Turtle L, Rowland-Jones S, Carroll M, Duncan CJA, Klenerman P, Dunachie S, Payne R, de Silva T

Publication type: Article

Publication status: Published

Journal: Nature Communications

Year: 2023

Volume: 14

Online publication date: 21/08/2023

Acceptance date: 02/08/2023

Date deposited: 05/08/2023

ISSN (electronic): 2041-1723

Publisher: Nature Publishing Group

URL: https://doi.org/10.1038/s41467-023-40592-4

DOI: 10.1038/s41467-023-40592-4


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
211153/Z/18/ZWellcome Trust
COV19- RECPLAS
Department of Health and Social Care
Huo Family Foundation
Medical Research Council
MR/X009297/1
National Institute for Health Research
MR/W02067X/1
MR/X001598/1
NIHR Newcastle Clinical Research Facility
PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium
Wellcome
UK Coronavirus Immunology Consortium (UK-CIC)
UKRI

Share